Severe COVID-19 patients display a back boost of seasonal 1

coronavirus-specific antibodies 2

- 3 Brenda M. Westerhuis PhD¹, Muriel Aguilar-Bretones MSc¹, Matthijs P. Raadsen MD¹, Erwin
- de Bruin BSc¹, Nisreen M.A. Okba PhD¹, Bart L. Haagmans PhD¹, Thomas Langerak MD¹, Henrik 4
- 5 Endeman MD PhD², Johannes P.C. van den Akker MD², Diederik A.M.P.J. Gommers MD PhD²,
- 6 Eric C.M. van Gorp MD PhD¹, Barry H.G. Rockx PhD¹, Marion P.G. Koopmans DVM PhD¹,
- 7 Gijsbert P. van Nierop PhD^{1,*}
- 8
- ¹Department of Viroscience and ²Intensive care unit of the Erasmus Medical Centre, 9
- Wytemaweg 80, 3015 CE, Rotterdam, the Netherlands 10
- *Correspondence: g.p.vannierop@erasmusmc.nl 11
- 12
- Keywords: SARS-CoV-2, hCoV-OC43, seasonal coronavirus, cross-reactivity, original antigenic 13

14 sin

- 15
- 16 Word count: 4550 (4100 excluding methods)
- Inserts: 1 table, 5 figures 17
- 18 Supplemental information: 6 figures

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 Abstract (135 words)

- 20 Severe acquired respiratory syndrome coronavirus-2 (SARS-CoV-2) is the cause of
- 21 coronavirus disease (COVID-19). In severe COVID-19 cases, higher antibody titers against
- 22 seasonal coronaviruses have been observed than in mild cases. To investigate antibody
- 23 cross-reactivity as potential explanation for severe disease, we determined the kinetics,
- 24 breadth, magnitude and level of cross-reactivity of IgG against SARS-CoV-2 and seasonal CoV
- 25 nucleocapsid and spike from 17 severe COVID-19 cases at the clonal level. Although patients
- 26 mounted a mostly type-specific SARS-CoV-2 response, B-cell clones directed against
- 27 seasonal CoV dominated and strongly increased over time. Seasonal CoV IgG responses that
- 28 did not neutralize SARS-CoV-2 were boosted well beyond detectable cross-reactivity,
- 29 particularly for HCoV-OC43 spike. These findings support a back-boost of poorly protective
- 30 coronavirus-specific antibodies in severe COVID-19 patients that may negatively impact *de*
- 31 *novo* SARS-CoV-2 immunity, reminiscent of original antigenic sin.

32 Introduction (892 words)

The introduction of the zoonotic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a pandemic of acute respiratory tract disease termed COVID-19¹. The majority of COVID-19 patients experience mild symptoms including fever, sore throat, cough, dyspnea, anosmia, ageusia and myalgia, none of which can be considered specific to this infection². In some patients, SARS-CoV-2 infection leads to acute respiratory distress syndrome (ARDS) with prolonged disease course requiring treatment at an intensive care unit (ICU) and resulting in a high mortality rate²⁻⁴.

Risks for developing ARDS and poor disease outcome are older age and factors 40 41 consistent with immune activation⁵. Correlates of protection for severe COVID-19 are not 42 defined in humans but antibodies likely are important. However, there is concern that suboptimal antibody responses may also be detrimental for COVID-19 outcome⁶. The 43 44 possibility of immune-mediated disease has been raised as a major concern for SARS-CoV-2 45 infection and an important consideration is the infection history and resulting immunological background against seasonal coronaviruses (CoV)^{6,7}. A lack of knowledge on specific features 46 of the induced host response to SARS-CoV-2 in ARDS patients hampers the development of 47 targeted treatment to prevent or overcome severe disease⁵. Therefore, there is an urgent 48 49 need for detailed insight in the SARS-CoV-2 immune response in the context of a CoVexperienced immune system. 50

51 For other viruses, several mechanisms have been described on how pre-existing 52 immunity to antigenically related viruses affect the outcome of infection. First, for influenza 53 and dengue viruses the immunological imprint of the initial infection dominates the host 54 response towards subsequent related infections for life^{8,9}. This mechanism, termed "original 55 antigenic sin" (OAS), relates to the propensity of adaptive immunity to preferentially fight

pathogens based on memory recall. Consequently, clones primed to target a specific epitope may dominate the response to target a new slightly different cross-reactive epitope and have reduced affinity and functionality, e.g. a poor neutralization potential for the new infection^{8–} ¹⁰. Moreover, OAS has also been linked to a delayed or weakened initiation of a new typespecific response¹⁰.

Second, for influenza virus increased antibody titers targeting viruses far beyond the 61 response against the first encountered antigen alone were observed^{11,12}. The observed boost 62 63 in neutralization titers was stratified on antigenic seniority, with highest titer increase towards more senior antigens¹². Also, a broad "back boost", extending beyond cross-64 reactivity, after infection or vaccination has been shown^{11,13}. This phenomenon has not yet 65 66 been described for any other viral infection but may have strong implications for vaccine design and the response to infection. Although a back-boost by vaccination may be useful to 67 maintain broad immunity to preceding strains, it may negatively affect the development of a 68 newly induced immune response, similar to OAS^{9–11}. 69

70 Structural homology between the ectodomain of SARS-CoV-2 Spike (S, SARS2-S_{ECTO}) or 71 nucleocapsid protein (N, SARS2-N) with those of other endemic human seasonal CoV such as hCoV-229E, -NL63, -HKU1 and -OC43 or recent epidemic strains such as SARS-CoV and Middle-72 73 East respiratory syndrome coronavirus (MERS-CoV) suggests that memory B-cells capable of expressing cross-reactive antibodies may pre-exist in patients^{14,15}. This is exemplified by the 74 cross-reactive antibody response towards SARS-CoV-2 in SARS-CoV infected individuals due 75 to high sequence homology (88.6% shared amino acids in N and 69.2% in S)^{14,16}. Structural 76 homology between SARS-CoV-2 and seasonal CoV is lower¹⁷, yet these viruses are highly 77 prevalent¹⁶. Repeated exposure to seasonal CoV may therefore also substantially contribute 78 to developing a SARS-CoV-2 reponse¹⁸. 79

80 A strong SARS2-N and SARS2-S IgM and IgG response is mounted in the vast majority 81 of infected individuals targeting the receptor binding domain (S_{RBD}), the outer- (S₁) and inner domains (S₂) to various extent¹⁹. In severe COVID-19 cases this response is dominated by IgG 82 targeting the S₂ domain^{16,19}. There was no evidence of substantial IgG cross-reactivity towards 83 SARS-CoV-2 in healthy controls^{16,19}. In contrast, COVID-19 patients displayed elevated serum 84 IgG titers against the majority of seasonal CoV N and S antigens which suggests that the IgG 85 responses against these viruses are correlated by undefined mechanisms. Strikingly, high 86 87 serum OC43-S_{ECTO} IgG titers are associated with COVID-19 disease severity, which might be related to stretches of amino acid sequence homology in S₂ ^{16,17}. Together, these studies 88 89 suggest that high antibody titers to seasonal CoV may associate with poor disease outcome 90 in COVID-19 patients and support the hypothesis that the immunological background is key. A limitation of serological studies is that monoclonal IgG cross-reactivity patterns cannot be 91 92 defined and the functional contribution of seasonal CoV-specific IgG clones to immune 93 protection or immunopathogenesis remains largely unknown.

94 At the clonal level, it was shown that pre-existing SARS-CoV-2 cross-reactive IgG memory B-cells predominantly target the SARS-CoV-2 S₂ with limited virus neutralization (VN) 95 potential²⁰. Besides a shared epitope that has been described in S₂ of SARS-CoV-2 and OC43²¹, 96 97 little is known on seasonal CoV IgG cross-reactivity patterns with SARS-CoV-2 and their functional contribution. Pre-existing CoV-specific B-cells may provide protection from SARS-98 CoV-2 infection by rapid production of cross-reactive antibodies that aid in viral clearance, 99 100 e.g. by a faster rise of cross-neutralizing antibodies from memory recall compared to initiating a primary humoral response^{22,23}. However, based on observations in other viral infections, 101 pre-existing immunity may also promote pathology⁷. 102

Here, we longitudinally enumerated and categorized type-specific and cross-reactive circulating B-cell clones targeting an array of N and S antigens from a broad selection of human CoV in order to gain insight in immune kinetics, magnitude, breadth and function towards SARS-CoV-2 in COVID-19 patients admitted to the intensive care unit (ICU).

107

108 Methods (485 words)

109 Patient characteristics and clinical specimen

PCR-confirmed COVID-19 patients²⁴ admitted to the ICU at the Erasmus Medical Center with 110 111 acute respiratory distress syndrome (ARDS) were included in a biorepository study (MEC-2017-417) and samples were analyzed according to the SARS-CoV-2 protocol (MEC-2020-112 113 0222) with approval from the medical ethical committee of the Erasmus MC. Personal or 114 deferred informed written consent was obtained after recovery or from a legal 115 representative, partner or family member of the participant respectively, all in compliance 116 with the Declaration of Helsinki. Plasma and peripheral blood mononuclear cells (PBMC) were 117 isolated from EDTA vacutainer blood collection tubes (BD biosciences) aliquoted and cryopreserved as described elsewhere²⁵. Weekly serum and EDTA blood samples for PBMC 118 119 isolation were collected where the initial sample was collected within 2 days after admittance 120 to the ICU until patients were released from the ICU. From patients 1–6, samples from the first three weeks were included in this study for longitudinal analysis. Additional serum 121 samples from later time points were included in the study if available. Additionally, 11 cross-122 123 sectionally sampled COVID-19 patients were selected based on differential clinical outcome 124 of infection. Six succumbed to, and five recovered from SARS-CoV-2 infection (Table 1).

125

126 B-cell profiling

127 B-cells were isolated from cryopreserved PBMC using the EasySep human CD19 positive 128 selection kit (Stem Cell technologies) according to manufacturer's instructions. Oligoclonal 129 cultures of 100-300 CD19+ B-cells per well were seeded in 96 wells U-bottom plates in AIM-V 130 AlbuMAX medium supplemented with 10% fetal bovine serum, penicillin-streptomycin (all 131 Invitrogen) and β -mercaptoethanol (Sigma) (B-cell medium). Oligoclonal B-cell cultures were 132 stimulated using 1000 L-CD40L cells that were growth arrested by 40Gray γ -irradiation, 50 U/ml IL-2 (Novartis), 10 ng/ml IL-10 (Peprotech), 25 ng/ml IL-21 (Peprotech) and 1 µg/ml R848 133 134 (Invivogen) for 48 hours and subsequently cultured for 12 days in B-cell medium supplemented with 25ng/ml IL-21. Culture supernatants were harvested and reactivity of 135 136 secreted IgG was determined using protein microarray analysis.

137

138 Protein micro-array analysis

Reactivity of secreted IgG in oligoclonal culture supernatants towards an array of CoV N and 139 140 S proteins was analyzed using protein microarray analysis (PMA) as described elsewhere²⁶. 141 Paired sera of the respective PBMC samples were included in the analysis. Microarray slides were scanned using a Powerscanner (Tecan, Switzerland). Background was determined for 142 143 each spot and mean fluorescence intensity signal (MFI, range 1 - 65,000) of two spots was 144 calculated for each serum or culture supernatant. For B-cell culture supernatants a cut-off was set at 1,000 MFI for all antigens based on the highest signal of non-reactive cultures. 145 146 Serum IgG titers were calculated using 4-parameter logistic regression with inflection point as titer²⁷. 147

149 Virus neutralization assays

Virus neutralization was determined by plaque reduction neutralization titers as previously
described¹⁷.

152

153 Statistical analysis

Serum IgG and virus neutralization titers and mean fluorescent intensity values of protein
 microarray analysis were ²Log transformed for regression analysis. P-values below 0.05 were
 considered statistically significant. All analyses were performed using 'R' and Graphpad Prism
 7 as previously described^{18,27}.

158

159 Results (1896 words)

160 Clinical characteristics of study participants

161 Seventeen severe COVID-19 patients with moderate to severe ARDS were included in this 162 study, shortly after being admitted to the ICU or the Erasmus MC, Rotterdam (Table 1). From six patients we included three or more longitudinal samples. All patients were tested RT-PCR 163 positive for SARS-CoV-2 and required mechanical ventilation during their stay at ICU. Five 164 females (mean age = 67.2y, range = 54-75y), and 12 males were included in the study (mean 165 age = 59.9y, range = 29-77y). Five patients died, nine recovered and three were transferred 166 to different hospitals for further treatment. Thirteen out of seventeen patients suffered from 167 one or more comorbidities, of which hypertension (n=6), and type 2 diabetes mellitus (n=5), 168 169 were the most common. Nine patients experienced thrombotic complication during their stay 170 at the ICU (Table 1).

172 Serum IgG titers towards a broad range of coronavirus N and S antigens increased after SARS-

173 CoV-2 infection in severe COVID-19 patients

174 All patients mounted a strong SARS-CoV-2 immune response shown by rising IgG titers against SARS2-S_{ECTO}, SARS2-S₁ and SARS2-S_{RBD} which peaked around 4 weeks post onset of clinical 175 176 symptoms (Figure 1A and Supplementary figure 1A for individual patients). These patients 177 were assumed never exposed to SARS-CoV and MERS-CoV. Nevertheless, there was a strong 178 IgG response towards all SARS-CoV antigens. Given the high structural similarities between N and S of SARS-CoV and SARS-CoV-2^{16,28}, likely a cross-reactive response was mounted. The 179 increase in MERS-S_{ECTO} IgG, but not MERS-N and MERS-S₁ IgG and highest amino acid 180 181 homology within S₂ with SARS-CoV-2 suggested this cross-reactive response targeted MERS-S₂¹⁷. 182

Besides the SARS-CoV-2 IgG response, serum IgG reactivity towards various, but not all seasonal CoV antigens, increased in longitudinally analyzed COVID-19 patients (Figure 1A and Supplementary figure 1A). All patients showed IgG reactivity towards at least one of the 229E, NL63, HKU1 or OC43 antigens (Supplementary figure 1A). Potential IgG cross-reactivity in serum responses refutes any firm conclusions on previous exposure against these CoV. For S, OC43-S_{ECTO} IgG titers were immunodominant at inclusion in all six patients and titers increased in five out of six patients during follow-up.

190

Severe COVID-19 patients showed outgrowth of circulating B-cells targeting a broad range of
coronaviruses

To analyze the kinetics of the IgG response we longitudinally enumerated circulating B-cell clones targeting CoV proteins using B-cell profiling on six severe COVID-19 patients (Supplementary figure 1B). Paired CD19+ B-cells isolated from PBMC of COVID-19 patients

196 were stimulated oligoclonally *in vitro* at a limiting density that was empirically tested to give 197 a clonal B-cell response. Supernatants were individually screened for IgG reactivity towards 198 all available CoV antigens using PMA. The number of reactive B-cells was normalized for the 199 number of screened B-cells in order to compare frequencies between different samples 200 (Figure 1B). Overall, the frequency and total reactivity of in vitro stimulated peripheral blood-201 derived B-cells was representative for the total serum IgG reactivity (Figure 1B and 202 supplementary figure 1B). Similar to serum IgG reactivity, all patients showed a strong 203 increase in SARS-CoV-2 reactive B-cells and the number of B-cell clones reactive towards 204 various seasonal CoV antigens increased after SARS-CoV-2 infection. However, the frequency 205 of HKU1-N reactive B-cells was higher than expected based on the low serum reactivity. 206 Potentially, this difference reflects a different level of B-cell activation in vitro and in vivo. The 207 linear outgrowth of B-cells reactive towards OC43-SECTO, SARS-SECTO, SARS2-SECTO, SARS2-S1 208 and SARS2-S_{RBD} displayed strikingly similar kinetics in their response (Figure 1C).

209

Coronavirus type-specific and cross-reactive IgG clones increased during SARS-CoV-2 infection 210 211 The outgrowth of B-cells that do not target SARS-CoV-2 antigens is potentially related to 212 cross-reactivity. Therefore, we analyzed the multiplex PMA profiles of in vitro stimulated B-213 cell cultures to address the level of cross-reactivity of monoclonal IgG. Profiles of CoV antigen-214 reactive cultures are shown for a representative patient (patient 4, Figure 2). N-reactive 215 clones from this donor showed substantial cross-reactivity between 229E-N, NL63-N and 216 HKU1-N at all time points (Figure 2A). Although individual clones with aberrant cross-217 reactivity can be identified in these patients, we hypothesize these contribute little to the 218 overall IgG response. A Pearson correlation test was used to calculate the strength and 219 robustness of cross-reactivity between each pair of antigens to identify cross-reactivity

patterns that significantly contribute to the induced immune response (Figure 2B). The level of cross-reactivity as calculated by Pearson correlation test varied slightly over time due to the limited number of clones per sample. Overall, the cross-reactivity patterns between 229E-N, NL63-N and HKU1-N became more apparent and statistically more significant when all clones from three time points (n=125) are combined for analysis (Figure 2B). OC43-N and MERS-N clones displayed no cross-reactivity and cross-reactivity between SARS-N and seasonal CoV was considered non-substantial (Figure 2A/B).

227 S-reactive IgG clones showed an increasing mostly SARS-CoV-2 type-specific response 228 with increasing numbers of detected SARS2-S_{ECTO} and SARS2-S₁ B-cell clones. Strong SARS2-229 S_{ECTO} and SARS2-S₁ cross-reactivity indicated that mostly shared epitopes within S₁ were 230 targeted in this patient (Figure 2C and D). The frequency and number of detected SARS2- S_{RBD} clones remained more or less stable, yet cross-reactivity towards SARS2-S_{ECTO} and SARS2-S₁ 231 232 increased over time suggesting maturation of the SARS-CoV-2 specific response. The initial 233 lack of cross-reactivity of SARS2-S_{RBD} towards SARS2-S_{ECTO} and SARS2-S₁ suggested that the 234 epitope(s) targeted by the SARS2-S_{RBD} clones at day 9 were sterically hindered or displayed in 235 an alternative conformation in the larger SARS-CoV-2 S proteins on PMA (Figure 2C). The increasing cross-reactivity suggests clones that target epitopes displayed on the outer surface 236 237 of S are naturally selected.

Strikingly, there was a dominant OC43-S_{ECTO}-specific response that increased over time. This response significantly cross-reacted with HKU1-S_{ECTO} and SARS-S_{ECTO}, but not SARS2-S_{ECTO} (Figure 2D). This suggests the outgrowth of OC43-S_{ECTO} clones is not driven by SARS-CoV-2 cross-reactivity. The limited cross-reactivity between OC43-S_{ECTO} and OC43-S₁ suggested these clones predominantly target S₂. The correlated response between the paired

S1 and SECTO antigens of NL63-, HKU1-, MERS-, SARS- and SARS-CoV-2 validated availability of
 shared epitopes in both antigens.

The total number of detected S_{ECTO}-reactive clones (n=363) outnumbered S₁-reactive clones (n=85) and showed greater cross-reactivity between different CoV compared to the S₁. These data suggested clones targeting S₂ are immunodominant and more cross-reactive in this donor.

249 For the other five longitudinally analyzed donors, similar patterns were observed with 250 i) high levels of cross-reactivity between 229E-N, NL63-N and HKU1-N but not SARS-N and 251 MERS-N ii) a mostly SARS-CoV-2 type-specific response that strongly increased over time, iii) 252 an OC43-S₂-specific response that increased over time with limited cross-reactivity towards 253 SARS-CoV-2. Notably, the N-reactivity of 1/6 patients showed increased cross-reactivity between OC43-N and other seasonal strains (Supplementary figure 6). OC43-SECTO-specific B-254 255 cells were immunodominant in 3/6 patients (Supplementary figure 1B) and the S₂ response 256 was immunodominant in 2/6 patients (Supplementary figures 2–6).

257

N-IgG selectively cross-reacted between seasonal coronaviruses while S-IgG showed complex
 cross-reactivity patterns involving all strains

In order to determine the overall pattern of IgG cross-reactivity between N and S of different
CoV in severe COVID-19 patients we pooled all available N (n=2039, Figure 3A) and S-reactive
IgG clones (n=2699, Figure 3B) from all 17 included donors. For N, Pearson correlation analysis
validated that 229E-N, NL63-N and HKU1-N IgG clones most substantially cross-reacted (range
R=0.52 - 0.72, all p<0.0001, Figure 3C). Additionally, weak yet highly significant correlations
between OC43-N and other seasonal CoV strains were observed (range R=0.066 - 0.14, all
p<0.003). Conversely, no significant cross-reactivity was detected between seasonal and

267 emerging CoV indicating different epitopes to be involved for these recent zoonotic strains268 (Figure 3C).

269	The combined analysis of all S-IgG clones showed complex cross-reactivity patterns,
270	including endemic seasonal and epidemic zoonotic strains (Figure 3D). All SARS-CoV and SARS-
271	CoV-2 S antigens positively correlated (range R=0.14 – 0.80, all p<0.0001). Additionally, all
272	corresponding S_1 and S_{ECTO} antigens positively correlated (range R=0.35 – 0.80, all p<0.0001)
273	validating availability of shared epitopes in paired antigens for all CoV strains.
274	Our cohort showed there was broad cross-reactivity within S1 between 229E-, NL63-,
275	HKU1- and OC43-CoV but not MERS-CoV. For MERS-CoV significant cross-reactivity was
276	restricted to S_{ECTO} , suggesting cross-reactive epitopes are mostly located in S_2 (Figure 3D).
277	
278	Correlated clonal IgG reactivity patterns showed in vivo expansion of OC43-S _{ECTO} specific B-
279	cells beyond detectable cross-reactivity
280	Given the synergistic outgrowth of OC43-S $_{ECTO}$ and SARS-CoV and SARS-CoV-2 S-reactive B-
281	cells in severe COVID-19 patients (Figure 1C) one would presume that SARS-CoV-2 cross-
282	reactivity drives in vivo expansion of OC43-S _{ECTO} -specific B-cells. However, cross-reactivity
283	between OC43-S $_{ECTO}$ and SARS-CoV-2 S antigens showed significant weak negative
284	correlations (range R=-0.038 – -0.088, range p=4,7x10 ⁻⁶ – 0.014) suggesting that OC43-S _{ECTO}
285	specific clones are unlikely to cross-react with SARS-CoV-2 S in severe COVID-19 patients
286	(Figure 3B). Indeed, the majority of OC43-S $_{ECTO}$ clones (752 out of 920 clones, 82%) did not
287	cross-react with SARS-CoV-2 indicating these were initiated prior to SARS-CoV-2 infection.
288	Due to lack of a pre-sample we cannot draw firm conclusions on pre-existence of SARS-CoV-
289	2 cross-reactive clones in this cohort.

Longitudinal analysis of OC43-S_{ECTO} clones in all 17 patients, grouped per week number post onset of symptom showed the average relative number of clones that cross-reacted with SARS-CoV-2 S antigens showed a moderate increase over 4 weeks (13 – 21%). The OC43-S_{ECTO}reactive clones that cross-reacted increasingly recognized epitopes in SARS2-S₁ and SARS2-S_{RBD} indicating there was natural selection of SARS-CoV-2 cross-reactive clones specific for the outer S domains (Figure 4).

296

297 No evidence for functional contribution of OC43-S_{ECTO}-specific IgG in virus neutralization

To determine what CoV-specific IgG functionally contribute to clearing SARS-CoV-2 infection via virus neutralization (VN) we correlated serum S reactive IgG to serum SARS-CoV-2 VN titers. All SARS-CoV and SARS-CoV-2 S antigens selectively positively correlated with serum SARS-CoV-2 VN titers but none of the other CoV S antigens. This is congruent with SARS-CoV/SARS-CoV-2 cross-reactivity patterns and other studies showing that S is the dominant antigenic target of neutralizing clones^{29,30}. Notably, no correlation was detected between VN and serum OC43-S_{ECTO} and OC43-S₁ IgG titers (Figure 5A).

305 To determine what circulating S-specific B-cells contribute to VN, the normalized S-306 reactive B-cell counts were correlated with paired serum SARS-CoV-2 VN titers. Similar to 307 serum IgG titers, SARS2-S_{ECTO}, SARS-S₁ and SARS2-S₁ correlated with serum VN titers. 308 Contrasting to serum titers, OC43-S₁ B-cell numbers showed a positive correlation with VN. Notably, the relatively low frequency of OC43-S₁-reactive B-cells (<0.01% of screened B-cells) 309 310 suggested the potential functional contribution of these clones to VN in vivo was limited. 311 Contrasting to serum IgG, SARS2-S_{RBD} B-cell counts did not reach significance in correlation 312 with VN titers (p=0.13), which may be related to the limited number of samples analyzed 313 (n=22). Notably, neither OC43-S_{ECTO}-specific serum IgG nor circulating specific B-cells

314 correlated with serum SARS-CoV-2 VN, which suggests that the strong OC43-S_{ECTO} response
 315 had no substantial contribution to SARS-CoV-2 neutralization (Figure 5B).

316

317 Discussion (1276 words)

Multiplex IgG analysis of culture supernatants of *in vitro* activated B-cell cultures at limiting dilutions allowed us to *i*) categorize strain-specific from cross-reactive monoclonal IgG, ii) distinguish pre-existing clones targeting seasonal CoV from newly induced SARS-CoV-2-type specific and cross-reactive clones, *iii*) perform in-depth analysis of humoral immune kinetics in severe COVID-19 patients. Together with paired serological analysis these data gave detailed insight in the magnitude, breadth and cross-reactivity patterns of the SARS-CoV-2 induced immune response in severe COVID-19 patients.

Severe COVID-19 patients displayed an evolving SARS-CoV-2 specific IgG response that 325 326 correlated with the increasing SARS-CoV-2 neutralization potential of serum during disease 327 progression. Additionally, these patients displayed a strong rise of pre-existing seasonal CoV-328 specific clones that did not correlate with SARS-CoV-2 neutralizing titers, which is suggestive 329 of OAS. Based on this mechanism, one would expect that cross-reactivity to SARS-CoV-2 would drive outgrowth of pre-existing seasonal CoV-specific B-cells. However, here we 330 331 observed a strong outgrowth of clones that selectively targeting seasonal CoV. Using Pearson 332 regression analysis, we were able to distinguish rare from substantial cross-reactivity 333 patterns. Although clones were identified that showed SARS-CoV-2 cross-reactivity, these had 334 a minor contribution to the overall SARS-CoV-2 response.

For N, very limited cross-reactivity was observed between seasonal and emerging CoV strains. Even though we could not confirm this for SARS-CoV-2, the high level of SARS2-N and SARS-N sequence homology (88.6%) and reported strong correlation between serum SARS2-

N and SARS-N IgG titers¹⁶ suggests SARS-N may be used as a proxy of SARS2-N. This suggests
the outgrowth of 229E-N, NL63-N and HKU1-N reactive IgG clones was not selectively driven
by cross-reactivity.

The outgrowth of seasonal CoV-reactive B-cell clones was most striking for OC43-S_{ECTO}. 341 342 OC-43-S_{ECTO}-reactive clones outnumbered others in the majority of patients and showed a synergistic outgrowth with the SARS-CoV-2-reactive B-cells. Of OC43-S_{ECTO} reactive clones 343 344 only a minor fraction cross-reacted with OC43-S₁ (66 out of 920 clones, 7%). This suggests the majority of OC43-S_{ECTO} clones target S₂, which corresponds with previous studies^{16,21}. The 345 346 fraction of OC43-S_{ECTO} clones that cross-reacted with SARS-CoV-2 was limited (168 out of 920 347 clones, 18%) but for the clones that did, reactivity was increasingly directed towards SARS2- S_1 and SARS2-S_{RBD} and not S_2 . As IgG targeting S_1 and S_{RBD} confer the strongest VN potential, 348 these OC43-S_{ECTO} clones contribute to evolving SARS-CoV-2-specific IgG response^{23,31}. 349

350 OC43-S₂ clones potentially have low-affinity reactivity towards SARS-CoV-2, that is 351 below the detection limit of protein microarray, which drives expansion of OC43-S_{ECTO} clones. This is of interest because low affinity antibodies, with consequentially a poor neutralizing 352 potential, can mediate engagement of Fc receptors (FcRs) on innate immune cells and 353 promote viral entry through a mechanism termed antibody-dependent enhancement (ADE). 354 355 This may either result in productive infection and increased viral spread – this was shown for flaviviruses³² – or promote inflammation and tissue damage, as was described for SARS-356 CoV^{33–35}. However, the level of OC43-S_{ECTO} clones that cross-react with SARS2-S₂ remained 357 stable over time, as determined by the OC43-S_{ECTO} clones that selectively cross-react with 358 359 SARS2-S_{ECTO} (Week 1, 7%; week 2, 4 %; week 3, 4% and week >4, 5%). If OC43-S_{ECTO} clones 360 were selectively expanding due to undetected low affinity cross-reactivity, one would expect 361 that clones that have detectable cross-reactivity to have a growth advantage. The reason for

this is that the clonal selection of B-cells is driven by the affinity of the B-cell antigen receptor and SARS-S_{ECTO}-specific T_H-cell-mediated linked recognition of antigens, the presence of which has been confirmed in an largely overlapping patient cohort²⁵.

We find no evidence of a functional contribution of OC43-SECTO reactive IgG to SARS-365 366 CoV-2 VN. OC43-S₁ specific clones did correlate with SARS-CoV-2 VN titers although these clones represent only a minor fraction of OC43-CoV specific clones. While it is possible that 367 368 OC43-S_{ECTO} specific IgG restrict viral replication by indirect mechanisms, they may also play 369 no role, or even have a detrimental effect by delaying the development of a type-specific response or by enhancing immune pathology³⁶. The previously reported selective association 370 371 of increased OC43-SECTO IgG reactivity in severe versus mild COVID-19 patients supports a potential role in immunopathology¹⁶. Unfortunately, the limited volume of B-cell culture 372 supernatants was insufficient to perform in-depth analysis of their affinity or function at the 373 374 clonal level and deserves follow-up studies.

Alternatively, the outgrowth of clones with reactivity towards the highly seroprevalent seasonal strains may relate to a general immune activation induced by a hyper-inflammatory state of the immune system³⁷. However, for individual patients, not all CoV-reactive B-cells show similar outgrowth after SARS-CoV-2 infection. Furthermore, the low serum IgG reactivity towards HKU1-N and relatively high frequency of HKU1-N-reactive clones suggests these B-cell are not activated *in vivo*. Together, these data do not support this hypothesis.

Overall, our data suggest that cross-reactivity towards SARS-CoV-2 has a minor contribution to the outgrowth of clones targeting seasonal CoV and *vice versa*. The boosted response involves a broad range of seasonal CoV strains. For influenza virus, the gradual antigenic evolution allows preceding exposures to different virus strains to be chronologically ordered to determine antigen seniority¹². For seasonal CoV, the order and time window at

which individuals were infected or reinfected cannot be deferred. Potentially, the strong and 386 387 dominant OC43-S_{ECTO} response observed in severe COVID-19 patients relates to antigenic seniority, but this cannot be confirmed. Regardless of the unknown timeline of preceding 388 infections, the outgrowth of seasonal CoV-specific clones is similar to the back-boost that was 389 initially described for influenza¹¹. Here, using antibody landscapes of hemagglutination 390 391 inhibition titers it was shown that infection or vaccination induced a broad increase in titers towards preceding viruses^{11,13}. Based on the antigenic distance it was calculated that the back 392 boost extended beyond cross-reactivity^{11,13}. However, this mechanism was never validated 393 by antigen binding at a clonal level or shown for any other infectious agents. To our 394 395 knowledge, we present the first data on a back boost of IgG clones towards a different virus 396 family and substantiate this mechanism with clonal reactivity.

For influenza, back-boost is considered to have a positive contribution to vaccine 397 398 response by helping maintain immunity towards a broad range of influenza viruses and allowing improved coverage by preemptive vaccination updates¹¹. Contrastingly, in OAS, 399 400 clones initiated by prior infections are shown to negatively impact *de novo* type-specific response and worsen clinical outcome^{8–10,13,38}. Whether the SARS-CoV-2-specific response is 401 402 hampered by back-boost of seasonal clones, similar to what has been described for OAS, is of 403 interest. Immune dominance of IgG reactivity towards seasonal CoV and the late peak SARS-404 CoV-2 response in these severe COVID-19 patients, 4 weeks after onset of clinical symptoms, suggests the initiation of the SARS-CoV-2 response may be hampered by proliferation of 405 406 seasonal CoV-specific clones.

In summary, the detailed insights in kinetics and cross-reactivity patterns of N and Sreactive IgG presented in this study will aid in the interpretation of serological assays and expands our understanding of how the humoral immune system responds towards a novel

CoV. Also, it shows that studies on in-depth functional characterization of the boosted or 410 411 newly induced antibody clones after SARS-CoV-2 infection, e.g. VN and ADE assays, are 412 warranted. These data are critical to identify correlates of protection and drivers of immunopathology for COVID-19 and may provide key insights for efficacy and safety testing 413 414 of future vaccines. Furthermore, the back boost of seasonal CoV IgG shows the immunological 415 background of individuals needs to be considered as an important factor in assessing the 416 quality and quantity of a newly initiated response towards SARS-CoV-2, either by infection or 417 vaccination.

418

419 Acknowledgements

420 This work has received funding from the European Union's Horizon 2020 research and 421 innovation program under grant agreements No. 874735 (VEO) and No. 101003589 422 (RECoVER) and the Netherlands Organisation for Health Research and Development 423 (ZONMW) grant agreement 10150062010008. We kindly acknowledge Felicity Chandler BSc 424 for technical assistance, Ron A.M. Fouchier PhD and Georges M.G.M. Verjans PhD for scientific discussions (all Erasmus MC, Rotterdam, the Netherlands) and Berend-Jan Bosch 425 426 PhD for supplying SARS-CoV-2 and OC43-S_{ECTO} antigens (University of Utrecht, the 427 Netherlands).

428

429 Competing interest statement

430 The authors have no competing interests

431 References

- 432 1. Zhu, N. *et al.* A novel coronavirus from patients with pneumonia in China, 2019. *N*.
- 433 Engl. J. Med. **382**, 727–733 (2020).
- 434 2. Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in
- 435 Wuhan, China. *Lancet* **395**, 497–506 (2020).
- 436 3. Wang, D. *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel
- 437 coronavirus-infected pneumonia in Wuhan, China. JAMA J. Am. Med. Assoc. **323**,
- 438 1061–1069 (2020).
- 439 4. Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel
- 440 coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **395**, 507–513
 441 (2020).
- 442 5. Wu, C. *et al.* Risk factors associated with acute respiratory distress syndrome and
- death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA
- 444 Intern. Med. **180**, 934–943 (2020).
- 445 6. Iwasaki, A. & Yang, Y. The potential danger of suboptimal antibody responses in

446 COVID-19. *Nature Reviews Immunology* **20**, 339–341 (2020).

- 447 7. Lee, W. S., Wheatley, A. K., Kent, S. J. & DeKosky, B. J. Antibody-dependent
- 448 enhancement and SARS-CoV-2 vaccines and therapies. *Nat. Microbiol.* 5, 1–7 (2020).
- 449 8. Halstead, S. B., Rohanasuphot, S. & Sangkawibha, N. Original antigenic sin in dengue.
- 450 Am. J. Trop. Med. Hyg. **32**, 154–156 (1983).
- 451 9. Rey, F. A., Stiasny, K., Vaney, M.-C., Dellarole, M. & Heinz, F. X. The bright and the
- 452 dark side of human antibody responses to flaviviruses: lessons for vaccine design.
- 453 *EMBO Rep.* **19**, 206–224 (2018).
- 454 10. Kim, J. H., Skountzou, I., Compans, R. & Jacob, J. Original antigenic sin responses to

- 455 influenza viruses. J. Immunol. **183**, 3294–3301 (2009).
- 456 11. Fonville, J. M. *et al.* Antibody landscapes after influenza virus infection or vaccination.
- 457 *Science (80-.).* **346**, 996–1000 (2014).
- 458 12. Lessler, J. *et al.* Evidence for antigenic seniority in influenza A (H3N2) antibody
- 459 responses in southern China. *PLoS Pathog.* **8**, 26 (2012).
- 460 13. Meade, P. et al. Influenza virus infection induces a narrow antibody response in
- 461 children but a broad recall response in adults. *MBio* **11**, 1–15 (2020).
- 462 14. Loganathan, S. K. et al. Rare driver mutations in head and neck squamous cell
- 463 carcinomas converge on NOTCH signaling. *Science* **367**, 1264–1269 (2020).
- 464 15. Lv, H. et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV
- 465 infections. *Cell Rep.* **31**, 1–20 (2020).
- 466 16. Wang, Y. *et al.* Kinetics of viral load and antibody response in relation to COVID-19
 467 severity. *J. Clin. Invest.* 130, (2020).
- 468 17. Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2-specific
- 469 antibody responses in coronavirus disease patients. *Emerg. Infect. Dis.* 26, 1478–1488
 470 (2020).
- 471 18. Westerhuis, B. M. et al. Homologous and heterologous antibodies to coronavirus
- 472 229E NL63 OC43 HKU1 SARS MERS and SARS-CoV-2 antigens in an age stratified
- 473 cross-sectional serosurvey in a large tertiary hospital in The Netherlands. *medRxiv*
- 474 (2020).
- 475 19. Long, Q. X. *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat.*476 *Med.* 26, 845–848 (2020).
- 477 20. Ng, K. *et al.* Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans.
- 478 *bioRxiv* 2020.05.14.095414 (2020). doi:10.1101/2020.05.14.095414

- 479 21. Ladner, J. T. et al. Epitope-resolved profiling of the SARS-CoV-2 antibody response
- 480 identifies cross-reactivity with an endemic human CoV. *bioRxiv Prepr. Serv. Biol.*
- 481 2020.07.27.222943 (2020). doi:10.1101/2020.07.27.222943
- 482 22. Shrock, E. et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity
- 483 and correlates of severity. *Science* (2020). doi:10.1126/science.abd4250
- 484 23. Wec, A. Z. *et al.* Broad neutralization of SARS-related viruses by human monoclonal
 485 antibodies. *Science (80-.).* 369, 731–736 (2020).
- 486 24. Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time
- 487 RT-PCR. *Eurosurveillance* **25**, 1–8 (2020).
- 488 25. Weiskopf, D. et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19
- 489 patients with acute respiratory distress syndrome. *Sci. Immunol.* **5**, 1–14 (2020).
- 490 26. Koopmans, M. *et al.* Profiling of humoral immune responses to influenza viruses by
- 491 using protein microarray. *Clin. Microbiol. Infect.* **18**, 797–807 (2012).
- 492 27. Westerhuis, B. et al. Specific memory B cell response in humans upon infection with
- 493 highly pathogenic H7N7 avian influenza virus. *Sci. Rep.* **10**, 3152 (2020).
- 494 28. Wu, A. et al. Genome composition and divergence of the novel coronavirus (2019-
- 495 nCoV) originating in China. *Cell Host Microbe* **27**, 325–328 (2020).
- 496 29. He, Y. et al. Identification of immunodominant sites on the spike protein of severe
- 497 acute respiratory syndrome (SARS) coronavirus: Implication for developing SARS
- 498 diagnostics and vaccines. J. Immunol. **173**, 4050–4057 (2004).
- Meyer, B., Drosten, C. & Müller, M. A. Serological assays for emerging coronaviruses:
 Challenges and pitfalls. *Virus Res.* **194**, 175–183 (2014).
- 501 31. Barnes, C. O. *et al.* Structures of human antibodies bound to SARS-CoV-2 spike reveal
- 502 common epitopes and recurrent features of antibodies. *Cell* **182**, 828-842.e16 (2020).

503 32. Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in

504 humans. *Science (80-.).* **358**, 929–932 (2017).

- 505 33. Wang, S. F. et al. Antibody-dependent SARS coronavirus infection is mediated by
- 506 antibodies against spike proteins. *Biochem. Biophys. Res. Commun.* **451**, 208–214
- 507 (2014).
- 508 34. Yip, M. S. *et al.* Antibody-dependent enhancement of SARS coronavirus infection and
- its role in the pathogenesis of SARS. *Hong Kong Med. J.* **22**, 25–31 (2016).
- 510 35. Jaume, M. et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies
- 511 trigger infection of human immune cells via a pH- and cysteine protease-independent
- 512 Fc R pathway. J. Virol. **85**, 10582–10597 (2011).
- 513 36. Monsalvo, A. C. et al. Severe pandemic 2009 H1N1 influenza disease due to

514 pathogenic immune complexes. *Nat. Med.* **17**, 195–199 (2011).

- 515 37. Bernasconi, N. L., Traggiai, E. & Lanzavecchia, A. Maintenance of serological memory
- 516 by polyclonal activation of human memory B cells. *Science (80-.).* **298**, 2199–2202
- 517 (2002).
- 518 38. Fierz, W. & Walz, B. Antibody dependent enhancement due to original antigenic sin
- and the development of SARS. *Front. Immunol.* **11**, 1–5 (2020).
- 520

521 Figure legends

522

Figure 1. Severe COVID-19 patients generate a strong SARS-CoV-2-specific IgG response and 523 display an increasing IgG response towards other coronaviruses. A) Longitudinal serum IgG 524 525 responses of six severe COVID-19 patients sampled three times with weekly intervals, 526 grouped per week number after onset of symptoms, towards a panel of nucleocapsid proteins 527 (N), the ecto- (S_{ECTO}) and head-domains (S_1) of spike or the SARS-CoV-2 (SARS2) receptor 528 binding domains (S_{RBD}). A SARS-CoV-2 response is mounted in all patients, together with a boost of seasonal human 229E, NL63, HKU1, OC43 and emerging MERS, SARS and SARS2 529 530 coronavirus antigens. Dotted line shows the assay background. B) Enumeration of paired in 531 vitro stimulated peripheral blood-derived B-cells at limiting density with IgG reactivity towards coronavirus antigens, normalized for the number of analyzed B-cells. Box represents 532 533 median, upper and lower quartile. Whiskers show range. C) OC43-SECTO, SARS-SECTO SARS2-534 S_{ECTO}/S_1 and spike receptor binding domain (S_{RBD}) specific B-cell clones show a synergistic linear outgrowth in the first four weeks after SARS-CoV-2 infection. Pearson correlation test, 535 solid line shows regression, dotted line shows the 95% confidence interval of the best-fit line. 536 537

Figure 2. Supernatants of *in vitro* stimulated B-cells of a representative donor shows clonal IgG cross-reactivity patterns towards different coronavirus strains. B-cells were isolated from peripheral blood samples of patient 4 and stimulated *in vitro* in oligoclonal cultures at limiting dilution to analyze IgG reactivity at the clonal level. This representative patient was analyzed at three consecutive weekly intervals starting at 9 days post onset of symptoms. A) Heatmaps of the mean fluorescent intensity (MFI) of clonal IgG reactivity towards N of a panel of coronaviruses. The number of single- and cross-reactive N-specific B-cells increased over

time after SARS-CoV-2 infection. **B**) Heatmaps of the Pearson regression coefficient (R, top panels) and significance (bottom panels) between N-reactivity of specific B-cell clones shows the level of cross-reactivity at weekly intervals and the clones of all time points combined. **C**) Heatmaps and **D**) regression analysis of S_{ECTO} , S_1 and S_{RBD} reactive IgG clones from the same patient is shown. Positive correlations (green shades) show clones likely cross-react, negative correlations (orange shades) show clones are likely to not cross-react. Significant associations are shown in red shades (p<0.05).

552

Figure 3. Combined analysis of reactive clones from all donors shows cross-reactivity 553 554 patterns between human seasonal and emerging coronaviruses. Reactivity of N (n=2039) 555 and S-reactive IgG clones (n=2699) identified in 17 severe COVID-19 patients was analyzed. 556 A) Heatmaps show the relative amount (top panel, grey shades) and number of IgG clones 557 reactive towards at least one (top left to bottom right diagonal) or two N antigens and the 558 relative frequency of cross-reactivity towards these antigens (bottom panel, purple shades, 559 numerator is shown in clone count heatmap, denominator is indicated on x-axis). B) Relative 560 amount and number (left panel) and frequency (right panel) of S-cross-reactive IgG clones. C) Pearson regression analysis of 2039 N reactive clones shows significant cross-reactivity 561 562 between all human seasonal coronaviruses. D) Regression analysis of 2699 SECTO, S1 and SRBD 563 reactive IgG clones shows broad cross-reactivity between human seasonal and emerging 564 coronavirus strains.

565

Figure 4. OC43-S_{ECTO}-reactive clones show minor yet antigenically evolving cross-reactivity
 towards SARS-CoV-2. All OC43-S_{ECTO}-reactive clones (n=920) from 17 patients were stratified
 by week number post onset of clinical symptoms. The proportion of single OC43-S_{ECTO} (blue)

and SARS-CoV-2 cross-reactive clones (grey) is shown (left pie). The cross-reactivity towards
a single (green colors), dual (yellow and orange colors) and three SARS-CoV-2 antigens (red
color) is depicted (right pie). The number of patients analyzed is indicated on the left. The
frequency and number of contributing clones for each cluster is shown inside and adjacent to
each part, respectively.

574

Figure 5. Serum IgG titers or normalized B-cell counts reactive towards OC43-S₁, SARS-575 576 SECTO/S1 and SARS2-SECTO/S1 correlate with serum SARS-CoV-2 virus neutralization titers, but 577 **not OC43-S**_{ECTO}. **A**) Linear correlation between ²Log transformed serum IgG and SARS-CoV-2 578 virus neutralization (VN) titers shows that only SARS-CoV and SARS-CoV-2 spike-reactive IgG 579 associate with VN. Horizonal dotted line shows the background of the assay. B) Normalized 580 counts of B-cells specific for SARS-S_{ECTO}, OC43-S₁, SARS-S₁ and SARS2-S₁ selectively correlate 581 with VN. 22 Serum samples and corresponding B-cell cultures of 17 patients were included in 582 these analyses. Solid line depicts the best-fit regression coefficient. Dashed line shows the 583 95% confidence of the best-fit line.

Patient ID	Gender	Age group	Days post onset symptoms at inclusion	Duration stay ICU (days)	Survival ¹	Thrombotic complication	Comorbidities
1	М	70-80	10	50	Y	Y	None
2	F	50-60	4	26	Y	Y	Hypertension
3	М	50-60	5	17	Y	Ν	Lung disease, Malignancy
4	F	60-70	9	21	Y	Ν	None
5	М	60-70	5	31	Y	Ν	Cardiac disease, Hypertension
6	Μ	50-60	12	45	Y	Y	Cardiac disease, Hypertension, Vascular disease, Type 2 diabetes, Lung disease
7	М	70-80	15	15	Y	Ν	Vascular disease, Type 2 diabetes
8	М	60-70	14	8	Y	Ν	Malignancy
9	М	50-60	15	10	Y	Y	Type 2 diabetes
10	F	70-80	20	13	Y	Ν	Hypertension
11	F	70-80	18	10	N	Y	Type 2 diabetes
12	М	20-30	9	10	N	Ν	None
13	F	70-80	16	8	N	Y	Cardiac disease, Vascular disease
14	М	60-70	33	26	N	Y	Hypertension
15	М	50-60	8	4	N	Y	Hypertension
16	М	70-80	29	11	Y	Y	None
17	М	60-70	13	5	Y	Ν	Cardiac disease, Type 2 diabetes

Table 1. Patient characteristics

¹Patients were followed up for at least 60 days.



Figure 1. Severe COVID-19 patients generate a strong SARS-CoV-2-specific IgG response and display an increasing IgG response towards other coronaviruses.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.10.20210070; this version posted October 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity.



Figure 2. Supernatants of in vitro stimulated B-cells of a representative donor shows clonal IgG cross-reactivity patterns towards different coronavirus strains.



Figure 3. Combined analysis of reactive clones from all donors shows cross-reactivity patterns between human seasonal and emerging coronaviruses.



Figure 4. OC43-S_{ECTO}-reactive clones show minor yet antigenically evolving cross-reactivity towards SARS-CoV-2.

It is made available under a



Figure 5. Serum IgG titers or normalized B-cell counts reactive towards OC43-S₁, SARS-S_{ECTO}/S₁ and SARS2-S_{ECTO}/S₁ correlate with serum SARS-CoV-2 virus neutralization titers, but not OC43-S_{ECTO}.